Anavex Life Sciences Corp (AVXL)

[nidan7500]

Power...agree they did they not get the AD memo on Amyloid Plaques. Also, a quick review of the topics from last weeks conference in Italy says that 50%+ of the AD presenters did not get it either.

You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe
Already a paid subscriber? Sign in to Endpoints News to remove this message.

Alzheon is focusing on a strategy very similar to the one adopted by Axovant $AXON: taking a failed drug and relying on existing data spied in a post hoc analysis to prove it’s both safe and potentially effective for a specific population of patients. Of course, the effort proved futile for Axovant, which watched its stock plummet nearly 80% when its Alzheimer’s drug crashed and burned in a Phase III study.
It doesn’t help Alzheon’s odds that its pursuing the amyloid beta hypothesis, which has defeated every drug thrown at it so far in a pivotal study. Eli Lilly $LLY tried this route for treating Alzheimer’s with solanezumab, but scrapped the program for treating symptomatic patients a couple years ago thanks to a series of Phase III failures. The drug is currently being studied to see if it can delay the development of preclinical patients.
Alzheon, which will list on the Nasdaq under the symbol $ALZH, plans to start a Phase III trial of ALZ-801 in the US and internationally in 2018, according to the company’s SEC statement. First, though, it will have to overcome some scathing reviews.